ArticleThe Prostate2009
Genetic and epigenetic inactivation of TNFRSF10C in human prostate cancer.
Article in The Prostate, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 32 citations in OpenAlex.
- Cardiovascular peptide markers are associated with age-related macular degeneration in the Bialystok PLUS general population cohort.Scientific reports · 2026Article
- Haplotype GWAS in Colorectal Cancer Patients with a Family History of Gastric or Prostate Cancer.International journal of molecular sciences · 2026Article
- Simulated microgravity impairs human NK cell cytotoxic activity against space radiation-relevant leukemic cells.NPJ microgravity · 2024Article
- Deciphering the Genetic Complexity of Classical Hodgkin Lymphoma: Insights and Effective Strategies.Current genomics · 2024Review
- Prognostic costimulatory molecule-related signature risk model correlates with immunotherapy response in colon cancer.Scientific reports · 2023Article
- Inhibition of Autophagy Amplifies Baicalein-Induced Apoptosis in Human Colorectal Cancer.Molecular therapy oncolytics · 2020Article
- Hypermethylation of tumor necrosis factor decoy receptor gene in non-small cell lung cancer.Oncology letters · 2020Article
- Hypermethylation ofIranian journal of public health · 2018Article
- Article
- The modularity and dynamicity of miRNA-mRNA interactions in high-grade serous ovarian carcinomas and the prognostic implication.Computational biology and chemistry · 2016Article
- TNFRSF10C copy number variation is associated with metastatic colorectal cancer.Journal of gastrointestinal oncology · 2016Article
- Putative Prostate Cancer Risk SNP in an Androgen Receptor-Binding Site of the Melanophilin Gene Illustrates Enrichment of Risk SNPs in Androgen Receptor Target Sites.Human mutation · 2016Article
- DNA Methylation Levels of Melanoma Risk Genes Are Associated with Clinical Characteristics of Melanoma Patients.BioMed research international · 2015Article
- Applicability of the methylated CpG sites of paired box 5 (PAX5) promoter for prediction the prognosis of gastric cancer.Oncotarget · 2014Article
- MicroRNA-143 is downregulated in breast cancer and regulates DNA methyltransferases 3A in breast cancer cells.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
- GATA4 and DcR1 methylation in glioblastomas.Diagnostic pathology · 2013Article
- Whole blood DNA aberrant methylation in pancreatic adenocarcinoma shows association with the course of the disease: a pilot study.PloS one · 2012Article
- DNA methylation in promoter region as biomarkers in prostate cancer.Methods in molecular biology (Clifton, N.J.) · 2012Article
- Aberrant DNA methylation and prostate cancer.Current genomics · 2011Article
- Promoter hypermethylation in prostate cancer.Cancer control : journal of the Moffitt Cancer Center · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundTNFRSF10C, is located on 8p21.3, one of the most frequently deleted loci in the genome of prostate cancer (PCa). Hypermethylation of TNFRSF10C promoter CpG island (CGI) had been reported in many tumors including PCa. However, the interplay between somatic deletion and promoter hypermethylation of TNFRSF10C on PCa development has not been investigated.
methodsMethylation status of promoter CGI and deletion status of the TNFRSF10C locus was investigated by bisulfite sequencing and Affymetrix SNP array, respectively, in 59 pairs of PCa tumor and matched normal samples with three PCa cell lines. TNFRSF10C gene expression changes in relation to cancer-associated genetic/epigenetic changes in clinical specimens, and change of TNFRSF10C expression before and after 5-aza-2'-deoxycytidine treatment in the PC3 PCa cell line was assessed by real-time RT-PCR.
resultsWe found that TNFRSF10C promoter CGI was differentially methylated in 46 of 59 primary cancers (78.0%). Hemizygous deletion at TNFRSF10C was found in 44 of the 59 prostate tumors (74.5%). Interestingly, in 94.9% of the tumors (56 out of 59), TNFRSF10C was either hemizygously deleted or its promoter CGI hypermethylated. Deletion and/or methylation of the TNFRSF10C gene were correlated with decreased mRNA expression of the gene in clinical specimens. Demethylation of the TNFRSF10C promoter CGI was accompanied by transcriptional re-activation of TNFRSF10C in the PCa cell line PC3.
conclusionWe found a notably high frequency of promoter CGI methylation and deletion of TNFRSF10C in PCa tissues. Our results indicated that inactivation of TNFRSF10C by chromosomal deletion and promoter methylation may play an important role in PCa development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.